Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 5.00 (0.29%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

BROKER RATINGS SUMMARY: Citi Raises BHP Billiton And Rio Tinto To Buy

Fri, 10th Jul 2015 08:37

LONDON (Alliance News) - The following shares received analyst recommendations Friday morning:
----------
FTSE 100
----------
CITIGROUP RAISES BHP BILLITON TO 'BUY' ('NEUTRAL') - PRICE TARGET 1400 (1500) PENCE
----------
CITIGROUP RAISES RIO TINTO TO 'BUY' - PRICE TARGET 2800 (2950) PENCE
----------
CITIGROUP CUTS RANDGOLD RESOURCES PRICE TARGET TO 4644 (5228) PENCE - 'NEUTRAL'
----------
CITIGROUP CUTS ANTOFAGASTA PRICE TARGET TO 600 (650) PENCE - 'SELL'
----------
EXANE BNP CUTS SMITHS GROUP PRICE TARGET TO 1090 (1125) PENCE - 'NEUTRAL'
----------
DEUTSCHE BANK CUTS BARCLAYS PRICE TARGET TO 287 (305) PENCE - 'BUY'
----------
EXANE BNP CUTS GKN PRICE TARGET TO 370 (380) PENCE - 'NEUTRAL'
----------
SOCGEN CUTS GKN PRICE TARGET TO 355 (400) PENCE - 'HOLD'
----------
DEUTSCHE BANK CUTS GLAXOSMITHKLINE PRICE TARGET TO 1490 (1540) PENCE - 'HOLD'
----------
EXANE BNP CUTS WEIR GROUP PRICE TARGET TO 1800 (1925) PENCE - 'NEUTRAL'
----------
EXANE BNP RAISES AB FOODS PRICE TARGET TO 3500 (3200) PENCE - 'OUTPERFORM'
----------
BERNSTEIN CUTS MARKS & SPENCER PRICE TARGET TO 535 (595) PENCE - MARKET-PERFORM
----------
BARCLAYS RAISES STANDARD LIFE PRICE TARGET TO 546 (520) PENCE - 'EQUAL WEIGHT'
----------
BARCLAYS RAISES ST JAMES'S PLACE PRICE TARGET TO 1148 (1106) PENCE - OVERWEIGHT
----------
BARCLAYS RAISES RSA INSURANCE PRICE TARGET TO 436 (428) PENCE - 'EQUAL WEIGHT'
----------
BARCLAYS RAISES LEGAL & GENERAL PRICE TARGET TO 289 (285) PENCE - 'OVERWEIGHT'
----------
BARCLAYS RAISES AVIVA PRICE TARGET TO 637 (632) PENCE - 'OVERWEIGHT'
----------
BARCLAYS RAISES ADMIRAL GROUP PRICE TARGET TO 1572 (1523) PENCE - EQUAL WEIGHT
----------
BARCLAYS RAISES PRUDENTIAL PRICE TARGET TO 1889 (1877) PENCE - 'OVERWEIGHT'
----------
BERENBERG RAISES BAE SYSTEMS TO 'BUY' ('HOLD') - TARGET 570 (530) PENCE
----------
FTSE 250
----------
HSBC CUTS SYNTHOMER PRICE TARGET TO 285 (300) PENCE - 'HOLD'
----------
EXANE BNP CUTS VESUVIUS PRICE TARGET TO 470 (480) PENCE - 'OUTPERFORM'
----------
EXANE BNP CUTS SPECTRIS PRICE TARGET TO 2415 (2500) PENCE - 'OUTPERFORM'
----------
EXANE BNP CUTS ROTORK PRICE TARGET TO 200 (220) PENCE - 'UNDERPERFORM'
----------
DEUTSCHE BANK CUTS DRAX GROUP PRICE TARGET TO 270 (370) PENCE - 'HOLD'
----------
GOLDMAN CUTS DRAX GROUP PRICE TARGET TO 285 (411) PENCE - 'NEUTRAL'
----------
BERNSTEIN CUTS DRAX GROUP PRICE TARGET TO 370 (420) PENCE - 'OUTPERFORM'
----------
EXANE BNP CUTS MELROSE PRICE TARGET TO 285 (310) PENCE - 'OUTPERFORM'
----------
EXANE BNP CUTS IMI PRICE TARGET TO 1050 (1080) PENCE - 'UNDERPERFORM'
----------
EXANE BNP RAISES HALMA PRICE TARGET TO 850 (800) PENCE - 'OUTPERFORM'
----------
SOCGEN CUTS IMI PRICE TARGET TO 1400 (1450) PENCE - 'BUY'
----------
PANMURE RAISES BREWIN DOLPHIN HLDGS PRICE TARGET TO 350 (300) PENCE - 'BUY'
----------
SOCGEN INITIATES CRODA WITH 'BUY' - TARGET 3050 PENCE
----------
CITIGROUP CUTS POLYMETAL PRICE TARGET TO 465 (522) PENCE - 'SELL'
----------
JPMORGAN CUTS ASHMORE GROUP PRICE TARGET TO 265 (275) PENCE - 'UNDERWEIGHT'
----------
GOLDMAN CUTS ASHMORE GROUP PRICE TARGET TO 330 (343) PENCE - 'NEUTRAL'
----------
CITIGROUP CUTS PETRA DIAMONDS PRICE TARGET TO 180 (215) PENCE - 'BUY'
----------
JPMORGAN RAISES HAYS PRICE TARGET TO 155 (145) PENCE - 'NEUTRAL'
----------
UBS CUTS LONMIN TO 'SELL' ('NEUTRAL') - TARGET 75 (130) PENCE
----------
CITIGROUP CUTS LONMIN PRICE TARGET TO 113 (144) PENCE - 'NEUTRAL'
----------
CITIGROUP CUTS KAZ MINERALS PRICE TARGET TO 270 (300) PENCE - 'BUY'
----------
CITIGROUP RAISES ACACIA MINING PRICE TARGET TO 312 (283) PENCE - 'NEUTRAL'
----------
BERENBERG RAISES DIGNITY PRICE TARGET TO 2260 (1850) PENCE - 'HOLD'
----------
UBS RAISES MICRO FOCUS PRICE TARGET TO 1460 (1420) PENCE - 'NEUTRAL'
----------
UBS RAISES HALFORDS GROUP PRICE TARGET TO 530 (485) PENCE - 'NEUTRAL'
----------
UBS RAISES DERWENT LONDON PRICE TARGET TO 3750 (3600) PENCE - 'NEUTRAL'
----------
BARCLAYS RAISES PHOENIX GROUP PRICE TARGET TO 794 (790) PENCE - 'UNDERWEIGHT'
----------
BARCLAYS CUTS LANCASHIRE HLDGS PRICE TARGET TO 456 (463) PENCE - 'UNDERWEIGHT'
----------
BARCLAYS CUTS HISCOX PRICE TARGET TO 607 (620) PENCE - 'UNDERWEIGHT'
----------
BARCLAYS RAISES ESURE GROUP PRICE TARGET TO 300 (288) PENCE - 'OVERWEIGHT'
----------
BARCLAYS CUTS AMLIN PRICE TARGET TO 391 (407) PENCE - 'UNDERWEIGHT'
----------
SOCGEN CUTS ASHMORE GROUP PRICE TARGET TO 325 (350) PENCE - 'BUY'
----------
BERENBERG CUTS BALFOUR BEATTY PRICE TARGET TO 250 (260) PENCE - 'BUY'
----------
MAIN MARKET AND AIM
----------
CITIGROUP CUTS SOUTH32 PRICE TARGET TO 110 (140) PENCE - 'BUY'
----------
CITIGROUP RAISES PETROPAVLOVSK PRICE TARGET TO 6 (5) PENCE - 'SELL'
----------
CITIGROUP CUTS POLYUS GOLD PRICE TARGET TO 185 (194) PENCE - 'NEUTRAL'
----------
CITIGROUP RAISES HOCHSCHILD MINING PRICE TARGET TO 75 (65) PENCE - 'SELL'
----------
CITIGROUP CUTS GEM DIAMONDS PRICE TARGET TO 155 (161) PENCE - 'NEUTRAL'
----------
CITIGROUP RAISES FERREXPO PRICE TARGET TO 38 (31) PENCE - 'SELL'
----------
BARCLAYS RAISES PARTNERSHIP PRICE TARGET TO 117 (111) PENCE - 'UNDERWEIGHT'
----------
BERENBERG CUTS PENDRAGON PRICE TARGET TO 44 (45) PENCE - 'BUY'
----------
By Arvind Bhunjun; arvindbhunjun@alliancenews.com; @ArvindBhunjun

Copyright 2015 Alliance News Limited. All Rights Reserved.

More News
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.